A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Recruiting now · Phase 1/Phase 2
Conditions studied: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Lineage Acute Leukemia, Mixed Phenotype Acute Leukemia, Acute Leukemia of Ambiguous Lineage
In brief
Phase 1 dose escalation will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of revumenib in participants with acute leukemia. In Phase 2, participants will be enrolled in 4 indication-specific expansion cohorts to determine the efficacy, short- and long-term safety, and tolerability of revumenib.
Key facts
- Study ID
- NCT04065399
- Run by
- Syndax Pharmaceuticals
- People needed
- 447
- Starts
- 2019-11-05
- Expected to finish
- 2027-12-15
- Last updated by the study team
- 2026-03-18
Who can join
Age: 0 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University Hospital Of Ulm, Universitatsklinikum Ulm — Ulm, Baden-Wurttemberg, Germany (enrolling)
- Shaare Zedek Medical Center — Jerusalem, Israel (enrolling)
- Royal North Shore Hospital — Saint Leonards, Australia (enrolling)
- Institut Gustave Roussy-Gustave Roussy Cancer Center -DITEP — Villejuif, France (enrolling)
- University of Leipzig — Leipzig, Germany (enrolling)
- Rambam Health Care Campus (RHCC) — Haifa, Israel (enrolling)
- Sir Charles Gairdner Hospital — Nedlands, Australia (enrolling)
- The University of Chicago Medical Center — Chicago, Illinois, United States (enrolling)
- University Health Network — Toronto, Canada (enrolling)
- Centre Hospitalier Lyon Sud — Pierre-Bénite, France (enrolling)
- Universitaetsmedizin Der Johannes — Gutenberg, Germany (enrolling)
- Universitaetsklinikum Hamburg-Eppendorf — Hamburg, Germany (enrolling)
- Emory Winship Cancer Institute — Atlanta, Georgia, United States (enrolling)
- Montefiore Medical Center — New York, New York, United States (enrolling)
- Duke University Medical Center — Durham, North Carolina, United States (enrolling)
- University of Colorado — Aurora, Colorado, United States (enrolling)
- Ohio State University — Columbus, Ohio, United States (enrolling)
- Oregon Health & Science University — Portland, Oregon, United States (enrolling)
- University of Pennsylvania — Philadelphia, Pennsylvania, United States (enrolling)
- University of Iowa Hospital — Iowa City, Iowa, United States (enrolling)
- Hospital Saint-Louis - APHP — Paris, France (enrolling)
- Centre Hospitalier Universitaire (CHU) de Bordeaux — Pessac, France (enrolling)
- Washington University in St. Louis School of Medicine — St Louis, Missouri, United States (enrolling)
- Alfred Hospital — Melbourne, Australia (enrolling)
- Hadassah Medical Center- Ein Kerem — Jerusalem, Israel (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.